CN114761436A - 用于治疗患有her2和her3阳性癌症的受试者的手段及方法 - Google Patents

用于治疗患有her2和her3阳性癌症的受试者的手段及方法 Download PDF

Info

Publication number
CN114761436A
CN114761436A CN202080083392.6A CN202080083392A CN114761436A CN 114761436 A CN114761436 A CN 114761436A CN 202080083392 A CN202080083392 A CN 202080083392A CN 114761436 A CN114761436 A CN 114761436A
Authority
CN
China
Prior art keywords
erbb
antibody
gene
cancer
nrg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080083392.6A
Other languages
English (en)
Chinese (zh)
Inventor
埃内斯托·伊萨克·沃瑟曼
莱昂纳多·安徳烈斯·西鲁尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Priority to CN202211199242.9A priority Critical patent/CN116327919A/zh
Publication of CN114761436A publication Critical patent/CN114761436A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080083392.6A 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法 Pending CN114761436A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211199242.9A CN116327919A (zh) 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024097 2019-10-24
NL2024097 2019-10-24
PCT/NL2020/050656 WO2021080428A1 (en) 2019-10-24 2020-10-23 Means and methods for treating subjects with her2 and her3 positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211199242.9A Division CN116327919A (zh) 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法

Publications (1)

Publication Number Publication Date
CN114761436A true CN114761436A (zh) 2022-07-15

Family

ID=68807359

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080083392.6A Pending CN114761436A (zh) 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法
CN202211199242.9A Pending CN116327919A (zh) 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211199242.9A Pending CN116327919A (zh) 2019-10-24 2020-10-23 用于治疗患有her2和her3阳性癌症的受试者的手段及方法

Country Status (9)

Country Link
US (1) US20220372166A1 (https=)
EP (1) EP4048702A1 (https=)
JP (2) JP7532514B2 (https=)
KR (1) KR20220103954A (https=)
CN (2) CN114761436A (https=)
AU (1) AU2020371040C1 (https=)
CA (1) CA3158609A1 (https=)
TW (1) TWI873210B (https=)
WO (1) WO2021080428A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
WO2022098233A1 (en) * 2020-11-04 2022-05-12 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010444A (es) * 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) * 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
IL269656B2 (en) * 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
US20210206875A1 (en) * 2017-03-31 2021-07-08 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
JP7296891B2 (ja) * 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
WO2022098233A1 (en) * 2020-11-04 2022-05-12 Merus N.V. Means and methods for treating subjects with erbb3 mutation positive cancer

Also Published As

Publication number Publication date
JP2022553104A (ja) 2022-12-21
EP4048702A1 (en) 2022-08-31
CA3158609A1 (en) 2021-04-29
TW202130664A (zh) 2021-08-16
CN116327919A (zh) 2023-06-27
AU2020371040A1 (en) 2022-05-12
AU2020371040B2 (en) 2025-10-09
KR20220103954A (ko) 2022-07-25
TWI873210B (zh) 2025-02-21
JP2024071393A (ja) 2024-05-24
JP7532514B2 (ja) 2024-08-13
WO2021080428A1 (en) 2021-04-29
JP7678175B2 (ja) 2025-05-15
US20220372166A1 (en) 2022-11-24
AU2020371040C1 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
US12247078B2 (en) ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
TW201642897A (zh) Ｈｅｒ２結合劑治療
JP7678175B2 (ja) Ｈｅｒ２及びｈｅｒ３陽性癌に罹患している対象を治療するための手段及び方法
US20240026029A1 (en) Means and methods for treating subjects with erbb3 mutation positive cancer
US20240425604A1 (en) Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
WO2025188180A1 (en) Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
HK40021172A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
CN120435311A (zh) 用pd-1轴结合拮抗剂和rna疫苗治疗胰腺癌的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination